Founded by Khwaja Abdul Hamied in 1935, Cipla has expanded to become one of the leading pharmaceutical companies, not just in India where it was set up but across the globe as well. Its headquarters is in Peninsula Business Park, Mumbai. It is listed on BSE Limited, National Stock Exchange of India Limited and Luxembourg Stock Exchange.
The company’s presence is currently felt across over 100 countries globally. Cipla has been approved by the FDA for the production of a wide range of drugs in the USA including prescriptive drugs, intermediates, drug production raw materials and multiple veterinary products.
Cipla’s strong market position has further been boosted by the approval it has received from multiple jurisdictions including Danish Medical Agency, MOH-Saudi Arabia, Department of Health-Canada, MCC-South Africa, and the SUKL-Slovak Republic, among others. Indeed, these approvals are evidence to the company’s enhanced global reach in the recent times.
Other than the sale of its manufactured products, the company also generates revenues in the form of technical fee. Further, it should be noted that the Mumbai-based firm also provides HIV/AIDS drugs freely to charity organizations and the needy patients. Cipla works closely with Médecins Sans Frontières and other health care organizations.
With its primary goal being improved access for all to high-quality medicine at affordable rates, Cipla has invested a lot in research. According to its website, Cipla is to become a leading pharmaceutical company globally founded in increased use of technology and investment in innovation in order to meet day to day medicine needs.
It is, therefore, no surprise that the company’s staff numbers over 20,000 employees across its global offices. Presently, it enjoys over $2 billion in turnover. Its continuous R & D innovations have helped the company project its mark across the globe. In total, the company has more than 1000 products in multiple therapeutic categories.
Amongst leading products of Cipla there are worldwide known ED drugs Tadacip, Silagra, and Suhagra. Tadacip is relatively a new drug on the market. However, the drug has already gained recognition as an effective treatment for erectile dysfunction. It joins Suhagra and Silagra, also produced by Cipla and known to be on the market for a while. The effectiveness of the drugs is evidenced by thousands of men.
Cipla has recently joined the movement that seeks to eliminate hepatitis by 2030, launched a Biotech manufacturing facility in South Africa, and set up a complex program for the production of antiretroviral drugs.